GV20 Therapeutics
- Business Model
- B2B
- Website
- gv20tx.com
- Total Funding
- $1.5M
- Last Round
- $1.5M Series BOct 2021
- Rounds
- 2
About
Biopharmaceutical company developing differentiated antibody therapeutics targeting novel cancer immunotherapy pathways including IGSF8.
Summary
GV20 Therapeutics is a Biotech company. It has raised $1.5M in total across 2 rounds, most recently a $1.5M Series B round in Oct 2021. Investors include Coatue Management and IDG Capital.
Tech & App Stack
2 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Oct 2021
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
Avenzo is a San Diego, CA-based biopharma company to in-license and develop the next generation o...
Clinical-stage biopharma developing precision medicines for cancer and other serious diseases usi...